The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Concepta Targets myLotus Development, New Products And Cost-Cuts

Wed, 29th Jan 2020 13:32

(Alliance News) - Concepta PLC on Wednesday unveilved a new marketing plan for myLotus product and said it will outsource its UK manufacturing, a move which has results in its chief operating officer standing down immediately.

The pregnancy testing kit developer said it will streamline the marketing team for the myLotus self-testing pregnancy kit, to establish "a more effective core team".

The firm said it will also launched a commercial website for the product, in a bid to establish a "cross-channel marketing strategy".

The company said myLotus is in the "early stages" of a commercial roll-out, with Concepta eyeing to boost the brand's presence on the Amazon.com Inc marketplace. Concepta also wants to "build open strong listings" on Walgreens Boots Alliance Inc's boots.com online store.

Concepta added: "In addition, the company expects to launch a modest clinical trial with a leading London hospital in the first quarter of 2020, to further highlight the accuracy of myLotus when measured against in-clinic processes, and demonstrate the value of this product to the patient."

Turning to cost-cutting, the company has already targeted a 30% cut in operating expenses, to be delivered in the year ending December.

In addition, the company is also mulling outsourcing its manufacturing to a UK-based third-party.

Concepta added: "This will have the added benefit of further reducing the company's operational cost-base and will allow the team to focus entirely on furthering the company's portfolio and commercial activities. As a result of this strategy, the company's Chief Operating Officer David Darrock, has agreed to stand down with immediate effect."

Looking to 2021, the company said it will build its product portfolio around myLotus and in the fertility health industry.

Concepta said: "A substantial portfolio product development programme is now underway, with new products expected to be ready for commercialisation in the next 12 months."

Shares in the company were 4.0% higher at 1.30 pence each in London on Wednesday afternoon.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
2 Dec 2020 14:37

UK EXECUTIVE CHANGE SUMMARY: Accrol Hires New CFO Newman From DS Smith

UK EXECUTIVE CHANGE SUMMARY: Accrol Hires New CFO Newman From DS Smith

2 Dec 2020 10:48

UK WINNERS & LOSERS SUMMARY: Concepta Rises On Covid-19 Test Kit

UK WINNERS & LOSERS SUMMARY: Concepta Rises On Covid-19 Test Kit

2 Dec 2020 09:55

Concepta Unveils Genomic Covid-19 Test And Plans Name Change

Concepta Unveils Genomic Covid-19 Test And Plans Name Change

2 Dec 2020 09:46

Concepta launches at-home Covid test, announces name change

(Sharecast News) - Healthcare company Concepta announced the launch of its DNA testing service on Wednesday, following the recent acquisition of the G...

23 Nov 2020 10:04

Concepta acquires outstanding shares in The Genome Store

(Sharecast News) - Healthcare company Concepta has acquired 100% of the outstanding share capital of The Genome Store in a deal worth as much as £...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.